Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid

Abstract

An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

Description

CROSS-REFERENCE TO EARLIER FILED APPLICATIONS [0001] The present application is a continuation-in-part of and claims the priority of U.S. application Ser. No. 11 / 479,979 filed Jun. 30, 2006, which is a continuation-in-part of PCT International Application No. PCT / US05 / 00082 filed Dec. 31, 2004, which claims benefit of the filing date of provisional application No. 60 / 533,628 filed Dec. 31, 2003, the disclosures of which are hereby incorporated by reference in their entirety.FIELD OF THE INVENTION [0002] The present invention relates to methods of and systems for administering formulations of sulfoalkyl ether cyclodextrin and corticosteroid, such as budesonide, by nebulization and inhalation. The invention also relates to methods of treating respiratory diseases or disorders of the air passageways. BACKGROUND OF THE INVENTION [0003] The delivery of a drug by inhalation allows deposition of the drug in different sections of the respiratory tract, e.g., throat, trachea, bronchi and alv...

AI Technical Summary

Benefits of technology

[0073] The present invention seeks to overcome the disadvantages present in known formulations. As such, a derivatized cyclodextrin-based, e.g., sulfoalkyl ether cyclodextrin (SAE-CD)-based, inhalable formulation is provided. The present formulation includes a corticosteroid as a principle active agent. The present formulation may provide enhanced solubility and / or enhanced chemical, thermochemical, hydrolytic and / or photochemical stability of the active agent or other ingredients in the formulation. Moreover, the present formulation may possess other advantages, e.g. enhanced drug delivery, increased rate of drug administration, reduced treatment time, reduced toxicity, ease of manufacture, assurance of sterility, improved stability, enhanced bioabsorption, no requirement of particle size control, increased output rate, increased total output, no concern for solid particle growth, enhanced pharmacokinetic profile, reduced corticosteroid-related side effects, enhanced pulmonary deposition, reduced oropharyngeal deposition, improved nebulization performance, and / or no need to confirm formation of a suspension, over other inhalable solution or suspension formulations containing a corticosteroid, such as budesonide.

Problems solved by technology

The main concerns about nebulizers, however, are their increased cost, reduced portability and the inconvenience of needing to prepare medication beforehand and the increased time requirement for administering a treatment.

They conclude that 2%-18% of the nebulizer's charge of budesonide was delivered from the suspension, meaning that budesonide delivery was incomplete resulting in a significant waste of drug.

However, it is well known that using current methods and formulations the greater part of an inhaled corticosteroid dose is swallowed and becomes available for oral absorption, resulting in unwanted systemic effects.

Since this oral component of corticosteroid drug delivery does not provide any beneficial therapeutic effect but can increase systemic side effects, it is desirable for the oral bioavailability of inhaled corticosteroid to be relatively low.

Due to a particular formulation employed, some corticosteroids are more likely to be deposited in the mouth and throat and may cause local adverse effects.

In contrast, particles that are larger than 5 mcm can be deposited in the mouth and throat, both reducing the proportion of particles that reach the lungs and potentially causing local adverse effects such as oral candidiasis and hoarseness (dysphonia).

A further disadvantage to the nebulization of budesonide suspensions is the need to generate very small droplets, MMAD of about <3 μm.

Generation of such particles is difficult.

The inhalation of drug particles as opposed to dissolved drug is known to be disadvantageous.

(Arch. Dis. Child (1986), 61, 1108-1110) suggest that nebulization of corticosteroid (in particular beclomethasone) solutions may be preferred over that of suspensions because the latter may be inefficient if the nebulized particles are too large to enter the lung in therapeutically effective amounts.

However, cosolvents, such as ethanol, polyethylene glycol and propylene glycol are only tolerated in low amounts when administered by inhalation due to irritation of the respiratory tract.

There are limits to acceptable levels of these cosolvents in inhaled products.

In addition, most potential hydrophobic therapeutic agents are not sufficiently soluble in these cosolvent mixtures.

None of the above-identified formulations has provided a method of improving the administration of a suspension-based unit dose formulation containing a corticosteroid.

When cyclodextrin formulations are administered by injection into the blood stream, the complex rapidly dissociates due to the effects of dilution and non-specific binding of the drug to blood and tissue components.

The underivatized parent cyclodextrins are known to interact with human tissues and extract cholesterol and other membrane components, particularly upon accumulation in the kidney tubule cells, leading to toxic and sometimes fatal renal effects.

This behavior is known for a large number of steroids which imposes serious limitations towards the use of γ-CD in liquid preparations. β-CD, however, does not complex well with a host of different classes of compounds.

However, the HP-β-CD still possesses toxicity that the SBE-CD does not.

While CAPTISOL® is a relatively new but known cyclodextrin, its use in the preparation of corticosteroid-containing solutions for nebulization has not previously been evaluated.

If the formulation being tested induces a significant amount of hemolysis, that formulation will generally be considered unsuitable for administration to a subject.

Administration of cyclodextrins into the lungs of a mammal may not be acceptable.

Even so, a number of studies regarding the use of cyclodextrins for inhalation have been reported although none have been commercialized.

When such situations do exist, they are unexpected.

Thus, the artisan would expect that SAE-CD derivatives would not be as suitable for use in solubilizing corticosteroids such as BMP or BDP.

Reportedly, HP-β-CD may be used to enhance the stability of a chemically labile drug, but the drug stability may be affected by the method of preparation of the formulation.

While heating of the solution in reservoir can reduce the viscosity of the solution and enhance formation of droplets, excessive heating could lead to drug degradation.

The ultrasonic nebulizer is quieter and provides faster delivery than the jet nebulizer, but ultrasonic nebulizers are more expensive and are not advised for the administration of the currently available steroid for nebulization.

However, there is no example of such combinations that are available as a solution for nebulization.

Although extremely effective in the treatment of asthma, inhaled corticosteroids can have a number of adverse side effects such as oral candidiasis, hoarseness (dysphonia), and pharyngitis.

Even though the art discloses inhalable solution formulations containing a corticosteroid and cyclodextrin, the results of the art are unpredictable.

In other words, the combination of one cyclodextrin with one drug does not suggest that another cyclodextrin may be suitable.

Images